The increasing prevalence for muscle-building peptides has fueled a large grey market, offering both unique possibilities and serious risks. These shadowy products, often procured from international suppliers, bypass established pharmaceutical channels, enabling availability at lower prices. However, the absence of quality control and stringent mon